Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Vanda Pharmaceuticals: Clinical Trials & FDA Approval Profile

Vanda Pharmaceuticals (Global / Institutional) sponsors 38 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 14 active protocols (10 recruiting now), 17 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)13.2%
Median Closed Enrollment vs National (145 pts)87 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Vanda Pharmaceuticals
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)38
Active Pipeline (Recruiting Now)14 (10)
Completed vs Stopped Early17 / 5 (13.2%)
Median Closed Actual Enrollment87 participants
Physical Hospital Site Disclosure2.1% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Explore interactive annual charts and M&A subsidiary rollups in the Vanda Pharmaceuticals Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI